Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms SUSTAIN; SUSTAIN JAPAN
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2018 Results published in the Diabetes Therapy.
- 15 Dec 2017 According to a Novo Nordisk media release, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes mellitus.